IV Fluids vs. Blood Transfusion: Composition, Indications, and Key Differences

Comparing Intravenous Fluid Therapy and Blood Product Transfusion

Both are administered intravenously but serve fundamentally different purposes.

Intravenous (IV) Fluids

Category	Examples	Composition	Primary Indications
Crystalloids	Normal Saline (0.9% NaCl), Lactated Ringer’s, Plasma-Lyte	Water + electrolytes ± buffer	Volume resuscitation, maintenance, electrolyte replacement
Colloids	Albumin 5%/25%, Hetastarch (limited use), Dextran	Water + electrolytes + large molecules (oncotic pressure)	Hypoalbuminemia, burns, specific volume expansion

• No oxygen-carrying capacity.
• No clotting factors.
• Risks: Volume overload, electrolyte imbalance, dilutional coagulopathy, infection (rare).

Blood Products

Component	Contents	Key Indications
Packed Red Blood Cells (PRBCs)	RBCs + additive solution (Hct ~55–65%)	Symptomatic anemia (Hb <7–8 g/dL), acute blood loss
Fresh Frozen Plasma (FFP)	Coagulation factors, albumin, immunoglobulins	Coagulopathy (INR >1.5), massive transfusion, warfarin reversal
Platelets	Platelet concentrate (apheresis or pooled)	Thrombocytopenia (<10K prophylactic, <50K active bleed/procedure)
Cryoprecipitate	Fibrinogen, Factor VIII, vWF, Factor XIII	Hypofibrinogenemia (<100 mg/dL), DIC, uremic bleeding
Whole Blood	All components (rarely used civilian)	Massive trauma (military, some trauma centers)

• Compatibility Testing: ABO/Rh typing, antibody screen, crossmatch (electronic or serologic).
• Risks: Transfusion reactions (febrile, allergic, TRALI, TACO, hemolytic — acute/delayed), infections (extremely rare with screening), immunomodulation.

Decision Framework

• Volume loss without anemia: Crystalloids.
• Anemia with hemodynamic compromise: PRBCs.
• Coagulopathy: FFP, platelets, cryo per labs.
• Massive Transfusion Protocol: 1:1:1 (PRBC:FFP:Platelets) + Ca²⁺, TXA, viscoelastic guidance.

Both require informed consent, patient identification verification, and monitoring during infusion.